LucyTx-1212
/ Lucy Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 28, 2024
Lucy Therapeutics Secures New Funding to Advance New Alzheimer’s and Parkinson’s Treatments
(Businesswire)
- "Lucy Therapeutics...announced it has raised $12.5 million in additional funding led by existing investors Engine Ventures and Safar Partners with new participation from Bill Gates, Parkinson’s UK, and the Michael J. Fox Foundation, which provided a $2 million non-dilutive grant. The fresh capital brings LucyTx’s total funding to date to more than $36 million. The investments will further the company’s research programs for Alzheimer’s and Parkinson's diseases and continue its development of a novel drug target for Rett syndrome....Using a novel approach to understand the mitochondrial roots of complex diseases, the biotech startup has three drug discovery programs in its pipeline, with IND filings planned in 2025."
Financing • IND • Alzheimer's Disease • Parkinson's Disease
October 13, 2022
Lucy Therapeutics Debuts Novel Therapeutic Agents for Parkinson’s Disease at Michael J. Fox Foundation Annual Conference
(Businesswire)
- "Lucy Therapeutics, Inc...announced promising preclinical data for multiple compounds in its lead program for Parkinson's disease, during an oral presentation at the Michael J. Fox Foundation's 14th annual Parkinson's Disease Therapeutics Conference on October 13, 2022, in New York City....Specifically, LucyTx-1209 and LucyTx-1212 are designed to target one of the functions of the protein complex F1F0-ATPase, which acts within the ETC. In their preclinical studies, the Lucy Therapeutics investigators demonstrated the investigational agents inhibited F1F0-ATPase to reverse mitochondrial dysfunctions known to lead to many key characteristics of Parkinson’s disease biology, including decreased levels of the cellular energy molecule ATP and death of neurons. The Lucy Therapeutics compounds also reduced levels of α-synuclein, the major constituent of Lewy bodies, which accumulate and are a pathological hallmark of PD."
Preclinical • CNS Disorders • Parkinson's Disease
1 to 2
Of
2
Go to page
1